Marc de Garidel is an emblematic figure in the pharmaceutical world. 

Firstly, because he joined Amgen in its early days and contributed to the development of this biotech, almost 30 years ago.

Secondly, because he led Ipsen to success in its commercial activities in the United States.

Finally, for the past five years, he has been exploring the emerging world of biotechnology, leading to major developments and agreements:

- Corvidia Therapeutics sold to Novo Nordisk in August 2020
- CinCor Pharma sold to AstraZeneca in February 2023 

- Today, he is the CEO of Abivax

In this extract, he explains the three key areas for choosing a promising biotech.

In this episode, he looks back on his career and explains how he made his choices, but also his vision of today's pharma perspectives.

-

1. Working together

THE FARM & CO develops your visibility in Pharma using the strength of your therapeutic commitment, the uniqueness of your personality and the power of social networks. Build a presence aligned with your values. Ghostwriting, content creation & conversational tools.

2. My newsletter

In my newsletter Pharma futurista, 2x/month, I jump into our society's evolutions and apply them to the future of Pharma. It's a short, 3-minute read on a subject that appeals to me. To receive it, you can subscribe here: https://nathalielahitte.substack.com/  or directly on my LinkedIn profile.

3. Get in touch with me! 

If you like the podcast, the best way to tell me or share your thoughts is on the Apple podcast app. It really helps me out, so don't hesitate to share!

If you'd like to ask me questions or follow my progress, you can do so on LinkedIn @nathalie lahitte .

Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.